14 October 2024, Melbourne: CUREator+ today announces its second funding round for Australian Biotech and Healthtech Innovators.
The CUREator+ program, a collaboration between CUREator by Brandon BioCatalyst and ANDHealth, aims to support Australian companies working on innovative biotech and health technologies with proven concepts and strong commercial potential.
CUREator+ is funded by the Federal Government’s $20 billion Medical Research Future Fund (MRFF) and aims to provide crucial financial support to Australia’s growing life sciences sector to foster a robust pipeline of high-impact biotech and health tech innovations in Australia.
The initial funding ranges from $1 million to $2.5 million for companies developing novel drugs, devices, diagnostics, and digital health solutions. Successful companies reaching phase one milestones can compete for additional funding of up to a maximum of $5 million to accelerate their development.
The program’s milestone-based funding model provides tailored resources at crucial development stages, ensuring that each company is supported and guided, enhancing the potential for successful commercialisation and long-term impact.
In addition to funding, successful applicants will receive expert support, including access to research collaborations, commercial capability-building, intellectual property development, governance, and operational management services.
Applications are now open for Australian companies, researchers, clinical innovators, and founders committed to transforming healthcare.
For more information and to apply, visit https://cureatorplus.grantplatform.com/.
